阿不都吾甫尔·依迪力斯,朱齐丰,刘先宝,王建安

• 1:浙江大学医学院附属第二医院心血管内科

摘要(Abstract)：

随着经导管主动脉瓣置换术适应证向外科手术中、低危人群拓展,经导管主动脉瓣置换术后瓣膜血栓逐渐引起人们的关注。瓣膜血栓形成的机制尚不明确。瓣膜血栓的预防、检测及治疗仍在探索阶段。本文将对瓣膜血栓的发生率及潜在机制、检测手段、临床表现、不良结局、预防及治疗等进行综述。

关键词(KeyWords)： 经导管主动脉瓣置换术;临床瓣膜血栓;亚临床瓣叶血栓;抗栓策略

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 阿不都吾甫尔·依迪力斯,朱齐丰,刘先宝,王建安

参考文献(References)：

• [1] Nishimura RA, Otto CM, Bonow RO,et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease:A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol,2017,70(2):252-289.
• [2] Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J,2017,38(36):2739-2791.
• [3] Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve peplacement with a balloon-expandable valve in low-risk patients. N Engl J Med,2019,380(18):1695-1705.
• [4] Popma JJ,Deeb GM,Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med,2019, 380(18):1706-1715.
• [5] Gleason TG,Reardon MJ,Popma JJ, et al. 5-year outcomes of selfexpanding transcatheter versus surgical aortic valve replacement in high-risk patients. J Am Coll Cardiol,2018, 72(22):2687-2696.
• [6] Douglas PS,Leon MB,Mack MJ, et al. Longitudinal hemodynamics of transcatheter and surgical aortic valves in the PARTNER trial.JAMA Cardiol, 2017, 2(11):1197-1206.
• [7] Didier R,Eltchaninoff H,Donzeau-Gouge P, et al. Five-year clinical outcome and valve durability after transcatheter aortic valve replacement in high-risk patients. Circulation,2018, 138(23):2597-2607.
• [8] Capodanno D,Petronio AS,Prendergast B, et al. Standardized defi nitions of structural deterioration and valve failure in assessing longterm durability of transcatheter and surgical aortic bioprosthetic valves:a consensus statement from the European Association of Percutaneous Cardiovascular Interventions(EAPCI)endorsed by the European Society of Cardiology(ESC)and the European Association for CardioThoracic Surgery(EACTS). Eur Heart J,2017, 38(45):3382-3390.
• [9] Vollema EM,Kong WKF,Katsanos S, et al. Transcatheter aortic valve thrombosis:the relation between hypo-attenuated leafl et thickening,abnormal valve haemodynamics, and stroke. Eur Heart J,2017, 38(16):1207-1217.
• [10] Sellers SL,Turner CT,Sathananthan J, et al. Transcatheter aortic heart valves:histological analysis providing insight to leafl et thickening and structural valve degeneration. JACC Cardiovasc Imaging,2019, 12(1):135-145.
• [11] Chakravarty T,S?ndergaard L,Friedman J, et al. Subclinical leafl et thrombosis in surgical and transcatheter bioprosthetic aortic valves:an observational study. Lancet,2017, 389(10087):2383-2392.
• [12] Makkar RR,Fontana G,Jilaihawi H, et al. Possible subclinical leafl et thrombosis in bioprosthetic aortic valves. N Engl J Med,2015, 373(21):2015-2024.
• [13] Pache G,Schoechlin S,Blanke P, et al. Early hypo-attenuated leafl et thickening in balloon-expandable transcatheter aortic heart valves. Eur Heart J,2016, 37(28):2263-2271.
• [14] Kappetein AP,Head SJ,Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation:the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg,2013, 145(1):6-23.
• [15] Hansson NC,Grove EL,Andersen HR, et al. Transcatheter aortic valve thrombosis:incidence, predisposing factors, and clinical implications. J Am Coll Cardiol,2016, 68(19):2059-2069.
• [16] Jose J,Sulimov DS,El-Mawardy M, et al. Clinical bioprosthetic heart valve thrombosis after transcatheter aortic valve replacement:incidence, characteristics, and treatment outcomes. JACC Cardiovasc Interv,2017, 10(7):686-697.
• [17] Leetmaa T,Hansson NC,Leipsic J, et al. Early aortic transcatheter heart valve thrombosis:diagnostic value of contrast-enhanced multidetector computed tomography. Circ Cardiovasc Interv, 2015, 8(4):e001596.
• [18] Latib A,Naganuma T,Abdel-Wahab M, et al. Treatment and clinical outcomes of transcatheter heart valve thrombosis. Circ Cardiovasc Interv,2015, 8(4):e001779.
• [19] Ruile P,Jander N,Blanke P, et al. Course of early subclinical leafl et thrombosis after transcatheter aortic valve implantation with or without oral anticoagulation. Clin Res Cardiol,2017, 106(2):85-95.
• [20] De Backer O,Dangas GD,Jilaihawi H, et al. Reduced leafl et motion after transcatheter aortic-valve replacement. N Engl J Med,2020, 382(2):130-139.
• [21] Blanke P,Leipsic JA,Popma JJ, et al. Bioprosthetic aortic valve leafl et thickening in the evolut low risk sub-study. J Am Coll Cardiol,2020,75(19):2430-2442.
• [22] Waksman R,Corso PJ,Torguson R, et al. TAVR in low-risk patients:1-year results from the LRT trial. JACC Cardiovasc Interv,2019, 12(10):901-907.
• [23] Yanagisawa, R,Tanaka M,Yashima F, et al. Early and late leafl et thrombosis after transcatheter aortic valvereplacement. Circ Cardiovasc Interv,2019, 12(2):e007349.
• [24] Trepels T,Martens S,Doss M, et al. Thrombotic restenosis after minimally invasive implantation of aortic valve stent. Circulation2009, 120(4):e23-e24.
• [25] Rheude T,Pellegrini C,Stortecky S, et al. Meta-analysis of bioprosthetic valve thrombosis after transcatheter aortic valve implantation. Am J Cardiol,2021,138:92-99.
• [26] Sannino A,Hahn RT,Leipsic J, et al. Meta-analysis of incidence,predictors and consequences of clinical and subclinical bioprosthetic leafl et thrombosis after transcatheter aortic valve implantation. Am J Cardiol,2020, 132:106-113.
• [27] Pache G,Blanke P,Zeh W, et al. Cusp thrombosis after transcatheter aortic valve replacement detected by computed tomography and echocardiography. Eur Heart J,2013, 34(46):3546.
• [28] Blanke P,Weir-McCall JR,Achenbach S, et al. Computed tomography imaging in the context of transcatheter aortic valve implantation(TAVI)/transcatheter aortic valve replacement(TAVR):an expert consensus document of the society of cardiovascular computed tomography. JACC Cardiovasc Imaging,2019, 12(1):1-24.
• [29] Ng ACT,Holmes DR,Mack MJ, et al. Leaflet immobility and thrombosis in transcatheter aortic valve replacement. Eur Heart J,2020, 41(33):3184-3197.
• [30] Jilaihawi H,Asch FM,Manasse E, et al. Systematic CT methodology for the evaluation of subclinical leafl et thrombosis. JACC Cardiovasc Imaging,2017, 10(4):461-470.
• [31] Córdoba-Soriano JG,Puri R,Amat-Santos I, et al. Valve thrombosis following transcatheter aortic valve implantation:a systematic review.Rev Esp Cardiol(Engl Ed),2015, 68(3):198-204.
• [32] Holmes DR,Mack MJ. Aortic valve bioprostheses:leafl et immobility and valve thrombosis. Circulation,2017, 135(18):1749-1756.
• [33] Dangas GD,Tijssen JGP,W?hrle J, et al. A Controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med,2020, 382(2):120-129.
• [34] Collet JP,Berti S,Cequier A, et al. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis:The randomized ATLANTIS trial. Am Heart J,2018, 200:44-50.
• [35] Jimenez Diaz VA,Tello-Montoliu A,Moreno R, et al. Assessment of platelet REACtivity after transcatheter aortic valve replacement:The REAC-TAVI Trial. JACC Cardio inter,2019, 12(1):22-32.
• [36] Piayda K,Zeus T,Sievert H, et al. Subclinical leafl et thrombosis.Lancet,2018, 391(10124):937-938.
• [37] Nijenhuis VJ,Brouwer J,Delewi R, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med,2020, 382(18):1696-1707.
• [38] Brouwer J,Nijenhuis VJ,Delewi R, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med,2020, 383(15):1447-1457.
• [39] Rodés-Cabau J,Masson JB,Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve:the ARTE(aspirin versus aspirin+clopidogrel following transcatheter aortic valve implantation)randomized clinical trial. JACC Cardiovasc Interv,2017, 10(13):1357-1365.
• [40] Stabile E,Pucciarelli A,Cota L, et al. SAT-TAVI(single antiplatelet therapy for TAVI)study:a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation.Int J Cardiol,2014, 174(3):624-627.
• [41] Cribier A,Eltchaninoff H,Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcifi c aortic stenosis：fi rst human case description. Circulation,2002, 106(24):3006-3008.